29 November 2006. Kursk. Pharmstandard announces today that OJSC Pharmstandard-Leksredstva in Kursk has launched three new production lines. This launch completes the next step in the modernization step of Pharmstandard’s facilities. Capital investment in OJSC Pharmstandard-Leksredstva was approximately 1 billion RUR ($37 million) in 2004, 2005 and the first half of 2006, while total capital investments of OJSC Pharmstandard stood at approximately 1.6 billion RUR ($59 million) during the same period.

As a result of this modernization Pharmstandard-Leksredstva will produce finished pharmaceuticals, including tablets, pills, powder, sachets, and syrups in line with current technical standards. New facilities have been introduced for tablets, sprays, aerosols and gelatin capsules.

The capacity of the new sprays and aerosols line is over 800 thousand bottles per month, producing “Ingalipt”, “Kameton”, “Dexpantenol”, “Lidocain”, “Termicon” and “Nitrocor”. The capacity of combined products (“Pentalgin-H”, “Pentalgin-ICN”, “Terpincod” and “Codelac”) facilities exceeds 5 million packs per month and the new facility for the cardiomedicine “Nitrocor” will produce more then 1 million packs per month. Additional capacities of more then 19 million pack per month have been created for traditional tablet formulations (“Analgin”, “Zitramon”, “Parazetamol” etc). The new lines were built in accordance with modern GMP standards and equipped by leading European companies: “Marchesini”, “Killian”, “Fetta”, “IMA”, “Coster” and “Favea”.

Commenting on today’s announcement, Igor Krylov, General Director of Pharmstandard said:

“Our facilities modernization and development allow us to proceed with our strategic objectives, including new product launches and cost control. Effective and modern production facilities are key to further improvements in our efficiency and productivity”.